UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) saw an uptick in trading volume on Thursday . 5,553 shares changed hands during trading, an increase of 447% from the previous session’s volume of 1,015 shares.The stock last traded at $271.71 and had previously closed at $268.39.

Wall Street Analysts Forecast Growth

UCBJF has been the subject of a number of recent analyst reports. Morgan Stanley restated an “overweight” rating on shares of UCB in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, October 6th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy”.

UCB Price Performance

The stock’s 50-day moving average is $272.25 and its 200-day moving average is $227.09. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.